Information Provided By:
Fly News Breaks for September 21, 2018
Sep 21, 2018 | 07:32 EDT
Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Zynerba with an Overweight rating and $21 price target. The analyst, who started coverage on seven Neuro-Innovator and Platform-Enabled Therapeutic companies, believes that "biotech has entered a golden age of innovation and productivity across many therapeutic areas."
News For ZYNE From the Last 2 Days
There are no results for your query ZYNE